American Oncology Research Taps AI for Faster Community Oncology Trials
Event summary
- American Oncology Research (AOR) and Meaningful Insights Biotech Analytics (MiBA) formed a strategic alliance on January 15, 2026 to integrate real-time data intelligence into community-based clinical research.
- The partnership aims to reduce the timeline between site selection and patient enrollment by leveraging MiBA’s AI-enhanced data ecosystem.
- AOR’s site management capabilities will be combined with MiBA’s Real-World Data (RWD) to provide near-real-time views of eligible patient populations.
- The alliance seeks to enhance provider engagement and trial equity by integrating research opportunities directly into the Electronic Medical Record (EMR) environment.
The big picture
The partnership addresses the longstanding challenge of disconnect between static clinical trial protocols and the dynamic reality of patient care. By embedding intelligent data workflows directly into the American Oncology Network (AON), the alliance aims to shift clinical research from a reactive administrative process to a proactive, data-informed discipline. This strategic move aligns with the broader industry trend towards leveraging AI and real-time data to enhance the efficiency and accessibility of clinical trials.
What we're watching
- Execution Risk
- How the integration of AI-powered intelligence into AOR’s clinical workflows will affect the speed and accuracy of patient matching and site feasibility.
- Regulatory Compliance
- Whether the partnership can sustain the proactive identification of demographic barriers and implement inclusive enrollment strategies during study design.
- Market Impact
- The pace at which this alliance will influence the broader adoption of real-time data intelligence in community-based clinical research.
Related topics